Generate Biomedicines Inc (NASDAQ:GENB) Receives $25.00 Average PT from Brokerages

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $25.00.

Several analysts recently commented on the stock. The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating for the company. Piper Sandler assumed coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target on the stock. Wall Street Zen raised shares of Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Finally, Guggenheim assumed coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective for the company.

Generate Biomedicines Stock Performance

Shares of NASDAQ:GENB opened at $11.44 on Tuesday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.